Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

ACCELAGEN PTY LTD

Home Clinical Trial Sponsors and OrganizationsACCELAGEN PTY LTD

ACCELAGEN PTY LTD

New Zealand

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

3

0 active

Approvals

125

Total approvals

Agencies

1

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

2

66.7%

Phase 3

1

33.3%

Trial Status Distribution

Recruiting

1

33.3%

Terminated

1

33.3%

Withdrawn

1

33.3%

Clinical Trials

Trials sponsored by this organization (3)

A Phase 1/2 randomized, placebo-controlled, multi-centre study to evaluate the safety and immunogenicity of a novel Receptor Binding Domain (RBD) COVID-19 Vaccine in Healthy Adults

Dec 202035 participants

A Phase 1/2 randomized, placebo-controlled, multi-centre study to evaluate the safety and immunogenicity of COVID-19 Vaccine in Healthy Adults

Aug 2020280 participants

A Placebo-Controlled Study to Evaluate the effect of the recombinant Bacillus Calmette–Guérin (BCG) vaccine VPM1002 on the Incidence or Disease Severity of SARS-COV-2/COVID-19 Among High-Risk Participants in Australia

Jun 20203,468 participants

Approvals

Approvals by Agency

TGA

Therapeutic Goods Administration

125

Approvals

Recent Approvals

ATTORA LA methylphenidate hydrochloride 30 mg modified release capsule bottle (408175)

ATTORA LA methylphenidate hydrochloride 40 mg modified release capsule bottle (408178)

ATTORA LA methylphenidate hydrochloride 20 mg modified release capsule bottle (408177)

ATTORA LA methylphenidate hydrochloride 60 mg modified release capsule bottle (408174)

ATTORA LA methylphenidate hydrochloride 60 mg modified release capsule bottle (408174)

ATTORA LA methylphenidate hydrochloride 10 mg modified release capsule bottle (408176)

ATTORA LA methylphenidate hydrochloride 40 mg modified release capsule bottle (408178)

ATTORA LA methylphenidate hydrochloride 10 mg modified release capsule bottle (408176)

ATTORA LA methylphenidate hydrochloride 30 mg modified release capsule bottle (408175)

ATTORA LA methylphenidate hydrochloride 20 mg modified release capsule bottle (408177)

News

No news articles found

On this page

Overview
Clinical Trials3
Approvals125
News

Back to Organizations